Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ASP5834 alone or with panitumumab in KRAS-altered advanced solid tumors
jRCT2031250769Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of ASP5834 and panitumumab in Non-hematologic malignancy, pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 1 more (4 arms), sponsored by Astellas Pharma. Primary endpoints: Dose-limiting toxicities, Adverse events and 8 more. Started Apr 2026; status: recruiting.
02
Drugs
ASP5834panitumumab
03
Conditions
Non-hematologic malignancypancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250769.